NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 976.2 DKK | +1.06% |
|
+0.90% | +39.84% |
| 06:23pm | European Equities Close Higher Wednesday; UK Survey Shows Robust Confidence in Business Activity Growth | MT |
| 03:12pm | NNIT Sells DKK200 Million Vendor Loan Note to Novo Holdings | MT |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
966
DKK
Average target price
953.5
DKK
Spread / Average Target
-1.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.84% | 621B | |
| +61.28% | 840B | |
| -5.09% | 354B | |
| +16.53% | 319B | |
| +7.87% | 297B | |
| +13.94% | 237B | |
| +15.82% | 221B | |
| +1.84% | 220B | |
| +11.20% | 169B | |
| -1.93% | 157B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Analysis Shows Use of Novo Nordisk's Wegovy, Ozempic for Weight Loss Declines After Two Years
